PTC Therapeutics, Inc. (PTCT) has a consensus analyst rating of Buy, based on 26 analysts covering the stock. Of those, 15 recommend buying, 9 recommend holding, and 2 recommend selling.
The analyst consensus price target for PTCT is $84.50, representing a +15.7% upside from the current price of $73.01. Price targets range from a low of $50.00 to a high of $120.00.
